Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:AGENASDAQ:ALRNNASDAQ:KALAOTCMKTS:PVOTF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGEAgeX Therapeutics$11.10-11.9%$3.67$11.07▼$35.71$11.99M1.183,849 shs3,700 shsALRNAileron Therapeutics$4.75$5.40$1.01▼$7.42$80.61M2.2264,087 shs67,714 shsKALAKALA BIO$6.50+2.7%$7.41$5.10▼$19.35$18.33M-1.8526,031 shs5,284 shsPVOTFBetterLife Pharma$0.13$0.03▼$0.38$21.70MN/A52,703 shs198,200 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGEAgeX Therapeutics0.00%0.00%-14.81%+4,396.20%+2,821.53%ALRNAileron Therapeutics+0.21%-19.90%-23.39%+1.06%+216.67%KALAKALA BIO-3.95%-9.57%-20.78%-11.96%-59.81%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGEAgeX TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AALRNAileron Therapeutics2.0721 of 5 stars3.53.00.00.02.91.70.0KALAKALA BIO3.6181 of 5 stars3.55.00.04.40.00.80.0PVOTFBetterLife PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGEAgeX TherapeuticsN/AN/AN/AN/AALRNAileron Therapeutics3.00Buy$19.00300.00% UpsideKALAKALA BIO3.00Buy$18.00176.92% UpsidePVOTFBetterLife PharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest PVOTF, AGE, KALA, and ALRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024ALRNAileron TherapeuticsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $19.004/2/2024KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $21.004/1/2024KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGEAgeX Therapeutics$140K85.63N/AN/A($16.07) per share-0.69ALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/AKALAKALA BIO$3.89M4.71N/AN/A$2.79 per share2.33PVOTFBetterLife PharmaN/AN/AN/AN/A$0.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGEAgeX Therapeutics-$14.80M-$13.03N/A∞N/A-10,424.65%N/A-120.90%5/13/2024 (Estimated)ALRNAileron Therapeutics-$15.73M-$3.38N/AN/AN/AN/A-130.32%-39.23%5/13/2024 (Estimated)KALAKALA BIO-$42.20M-$17.94N/AN/AN/AN/A-281.02%-65.57%5/14/2024 (Estimated)PVOTFBetterLife Pharma-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/ALatest PVOTF, AGE, KALA, and ALRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023KALAKALA BION/A-$3.18-$3.18-$3.18N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGEAgeX TherapeuticsN/AN/AN/AN/AN/AALRNAileron TherapeuticsN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGEAgeX TherapeuticsN/A0.130.36ALRNAileron TherapeuticsN/A4.174.17KALAKALA BIO5.106.336.33PVOTFBetterLife PharmaN/A3.623.62OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGEAgeX Therapeutics12.50%ALRNAileron Therapeutics90.89%KALAKALA BIO24.61%PVOTFBetterLife PharmaN/AInsider OwnershipCompanyInsider OwnershipAGEAgeX Therapeutics6.50%ALRNAileron Therapeutics5.57%KALAKALA BIO13.40%PVOTFBetterLife Pharma34.77%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGEAgeX Therapeutics51.08 million1.01 millionNot OptionableALRNAileron Therapeutics616.97 million16.03 millionNot OptionableKALAKALA BIO432.82 million2.44 millionNot OptionablePVOTFBetterLife PharmaN/A171.41 millionN/ANot OptionablePVOTF, AGE, KALA, and ALRN HeadlinesSourceHeadlineJardiance and Ofev propel Boehringer’s human pharma salesmsn.com - April 17 at 2:48 PMVertex Pharma scientist talks about the long road to developing non-addictive painkillersabcnews.go.com - April 15 at 12:36 PMPharmacy defends Eli Lilly off-label drug suitlifesciencesipreview.com - April 11 at 2:26 PMBetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conferencetmcnet.com - April 11 at 9:26 AMVictory Over Big Pharma Will Take More Than the IRAmsn.com - April 4 at 8:20 PMLiberals Need to Be Radicalsprospect.org - April 4 at 10:19 AMPharma is betting big on connecting potential patients to its medications. It's just the beginningendpts.com - April 3 at 2:37 AMAEVIS VICTORIA SA - Fabrice Zumbrunnen to become…pharmiweb.com - March 13 at 4:50 AMPresence of Particulates Prompts Recall of Treprostinil Injectionempr.com - March 13 at 4:50 AMIn Vietnam’s Mekong Delta, the lure of moving to the city grows even stronger amid climate shockskdvr.com - March 12 at 10:24 PMAmerica’s Last Top Modelsnewyorker.com - March 12 at 10:24 PMProfile: Xi Jinping the reformerchinadaily.com.cn - March 12 at 12:23 PMBetterLife Pharma Inc.: BetterLife's 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton Universityfinanznachrichten.de - March 4 at 1:49 PMIndia continues fast economic growth but FDI falls sharplyglobal.chinadaily.com.cn - March 1 at 8:26 AMGenesisCare Completes Reorganisation and Emerges from Chapter 11pharmiweb.com - February 19 at 3:51 PMImmigrant Execs Give Back to OCocbj.com - February 5 at 9:25 PMThe tragedy of Leonard Farruku, the gifted young musician whose dream of a better life ended on the Bibby Stockholmtheguardian.com - February 5 at 9:25 PMWeight loss drugs could create the first $1 trillion pharma companiesmsn.com - February 1 at 9:57 AMRoff: Medicare prescription price controls will hurt seniorsnews-journal.com - January 31 at 11:57 PMBudget 2024 Live Updates: Infrastructure, income tax, fiscal deficit, job creation announcements expected from FM Sitharaman's Union Budgettimesofindia.indiatimes.com - January 31 at 11:57 PMBetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001finance.yahoo.com - January 2 at 10:19 AMBig Pharma scrambles to feed demand for weight-loss treatments amid rising U.S. obesity ratesnbcnewyork.com - November 16 at 5:01 PMBig Pharma scrambles to feed demand for weight-loss treatments amid rising US obesity ratesmsn.com - November 16 at 12:01 PMUS Patent and Trademark Office Publishes BetterLife's Comprehensive Patent for BETR-001 and Other LSD Derivativestmcnet.com - November 15 at 12:13 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s Portfolio5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come2 Data Storage Device Stocks Thriving From the AI BoomApril 2, 2024 7:25 AMView 2 Data Storage Device Stocks Thriving From the AI BoomMicron Technology Results Proves AI is Driving Storage DemandMarch 26, 2024 7:35 AMView Micron Technology Results Proves AI is Driving Storage DemandYou Can Follow BlackRock’s Market View for Your MoneyApril 12, 2024 10:00 AMView You Can Follow BlackRock’s Market View for Your MoneyAll Headlines Company DescriptionsAgeX TherapeuticsNYSE:AGEAgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.Aileron TherapeuticsNASDAQ:ALRNAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.KALA BIONASDAQ:KALAKALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.BetterLife PharmaOTCMKTS:PVOTFBetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.